ANGLE plc

LSE AGL.L

ANGLE plc Price to Sales Ratio (P/S) on January 14, 2025: 16.63

ANGLE plc Price to Sales Ratio (P/S) is 16.63 on January 14, 2025, a -46.24% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.

ANGLE plc 52-week high Price to Sales Ratio (P/S) is 34.15 on May 15, 2024, which is 105.28% above the current Price to Sales Ratio (P/S).
ANGLE plc 52-week low Price to Sales Ratio (P/S) is 10.84 on December 20, 2024, which is -34.82% below the current Price to Sales Ratio (P/S).
ANGLE plc average Price to Sales Ratio (P/S) for the last 52 weeks is 19.90.

Key data

Date	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield

LSE: AGL.L

ANGLE plc

CEO	Mr. Andrew David William Newland ACA, Meng
IPO Date	March 17, 2004
Location	United Kingdom
Headquarters	Surrey Research Park
Employees	150
Sector	Health Care
Industries Biotechnology Medical Instruments Pharmaceuticals

Description

ANGLE plc, a medical diagnostic company, engages in developing cancer diagnostics products. The company develops and commercializes Parsortix cell separation system, which captures and harvests circulating tumor cells in metastatic breast cancer patient blood; and HyCEAD multiplex analysis system for routine and focused multiplex analysis of DNA, RNA or protein biomarkers. The company was founded in 1994 and is based in Guildford, the United Kingdom.

Key trends

Past 5 years